MetLife Investment Management
VIR icon

MetLife Investment Management’s Vir Biotechnology VIR Stock Holding History

MetLife Investment Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$732K Buy
71,822
+21,276
+42% +$202K ﹤0.01% 1694
2026
Q1 		$453K Buy
50,546
+12,824
+34% +$102K ﹤0.01% 1800
2025
Q4 		$227K Sell
37,722
-15,207
-29% -$90.5K ﹤0.01% 2206
2025
Q3 		$302K Sell
52,929
-1,551
-3% -$7.93K ﹤0.01% 2084
2025
Q2 		$275K Hold
54,480
– – ﹤0.01% 2010
2025
Q1 		$353K Sell
54,480
-1,013
-2% -$9.01K ﹤0.01% 1899
2024
Q4 		$407K Buy
55,493
+4,758
+9% +$37.5K ﹤0.01% 1911
2024
Q3 		$380K Hold
50,735
– – ﹤0.01% 1935
2024
Q2 		$452K Buy
50,735
+6,578
+15% +$63.1K ﹤0.01% 1776
2024
Q1 		$447K Hold
44,157
– – ﹤0.01% 1737
2023
Q4 		$444K Hold
44,157
– – ﹤0.01% 1760
2023
Q3 		$414K Hold
44,157
– – ﹤0.01% 1749
2023
Q2 		$1.08M Buy
44,157
+6,400
+17% +$161K 0.01% 1225
2023
Q1 		$879K Hold
37,757
– – 0.01% 1284
2022
Q4 		$956K Hold
37,757
– – 0.01% 1236
2022
Q3 		$728K Hold
37,757
– – 0.01% 1373
2022
Q2 		$962K Buy
37,757
+4,581
+14% +$107K 0.01% 1226
2022
Q1 		$853K Buy
33,176
+11,534
+53% +$342K 0.01% 1435
2021
Q4 		$906K Hold
21,642
– – 0.01% 1170
2021
Q3 		$942K Hold
21,642
– – 0.01% 1142
2021
Q2 		$1.02M Buy
21,642
+1,270
+6% +$57.7K 0.01% 1149
2021
Q1 		$1.04M Sell
20,372
-2,484
-11% -$134K 0.01% 1134
2020
Q4 		$612K Hold
22,856
– – 0.01% 1376
2020
Q3 		$785K Buy
22,856
+2,273
+11% +$97.9K 0.01% 1150
2020
Q2 		$843K Buy
20,583
+17,201
+509% +$577K 0.01% 1097
2020
Q1 		$116K Buy
+3,382
New +$90.9K ﹤0.01% 1996

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SB Investment Advisers (UK)
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

MetLife Investment Management's VIR Position: Q2 2026 in Review

MetLife Investment Management increased its Vir Biotechnology (VIR) stake by 42% in Q2 2026, buying an estimated $202K and bringing the position to 71,822 shares worth $732K. The position accounts for ﹤0.01% of the portfolio, ranked #1694.

MetLife Investment Management first reported a position in VIR in Q1 2020 and has held it in 26 quarters since. The position peaked at $1.08M in Q2 2023. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • MetLife Investment Management held 71,822 shares of Vir Biotechnology worth $732K as of Q2 2026.
  • MetLife Investment Management bought 21,276 Vir Biotechnology shares in Q2 2026, an estimated $202K.
  • Vir Biotechnology made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #1694 holding.
  • MetLife Investment Management first reported a position in Vir Biotechnology in Q1 2020 and has held it in 26 quarters since.
  • MetLife Investment Management's Vir Biotechnology position peaked at $1.08M in Q2 2023.
  • 237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.